MiMedx Group, Inc. — Q2 2022 Form 10-Q Summary
Business Context and Reporting Period
MiMedx is a placental biologics company developing and distributing human placental tissue allografts, primarily for advanced wound care, surgical recovery, and musculoskeletal applications. The filing covers the three and six months ended June 30, 2022 and was filed August 2, 2022.
The company markets Section 361 advanced wound care products, including tissue and umbilical-cord products. Following the expiration of FDA enforcement discretion on May 31, 2021, MiMedx stopped marketing its micronized and particulate Section 351 products in the United States pending potential FDA biologics license approval. AMNIOEFFECT was introduced through a limited market release in June 2022.
Key Financial Metrics
| Metric | Q2 2022 | Q2 2021 | Change |
|---|---|---|---|
| Net sales | $66.9 million | $68.2 million | Down 1.9% |
| Gross profit | $55.1 million | $55.4 million | Down 0.6% |
| Gross margin | 82.3% | 81.3% | Up 100 basis points |
| Operating loss | $9.6 million | $0.4 million | Greater loss |
| Net loss | $10.9 million | $1.8 million | Greater loss |
| Net loss available to common stockholders | $12.5 million | $3.3 million | Greater loss |
| Basic and diluted loss per share | $0.11 | $0.03 | Greater loss |
| Adjusted EBITDA | $(1.0) million | $3.1 million | Down $4.1 million |
| Adjusted EBITDA margin | (1.4%) | 4.6% | Down 600 basis points |
For the six months ended June 30, 2022, net sales were $125.8 million versus $128.1 million in the prior-year period. Gross profit was $104.0 million versus $105.7 million, and gross margin was 82.7% versus 82.5%. Net loss was $21.4 million versus $10.2 million, while Adjusted EBITDA was $(2.7) million versus $8.1 million.
Revenue Mix and Material Changes
- Q2 Advanced Wound Care revenue increased 11.6% to $66.2 million. Tissue/Other revenue rose 12.9% to $60.3 million, while Cord revenue was essentially flat at $5.9 million.
- Q2 Section 351 revenue declined 92.5% to $0.6 million from $8.6 million, with 2022 sales derived from outside the United States.
- Advanced Wound Care growth substantially offset, but did not fully replace, the loss of U.S. Section 351 revenue.
- Q2 selling, general and administrative expense increased 4.1% to $55.8 million, reflecting higher travel, commissions, and bad debt expense, including $2.2 million of Q2 bad debt expense.
- Research and development expense increased 35.7% to $5.5 million as the company expanded personnel and development activities.
- Investigation, restatement, and related expense was $3.2 million, compared with a $2.1 million benefit in Q2 2021, when insurance recoveries and negotiated reductions benefited results.
- Q2 2021 included a $1.0 million Section 351 inventory write-down; no significant unusual inventory write-down was recorded in Q2 2022.
Cash Flow, Liquidity, Debt, and Capitalization
| Metric | June 30, 2022 | December 31, 2021 |
|---|---|---|
| Cash and cash equivalents | $72.5 million | $87.1 million |
| Current assets | $131.0 million | $148.5 million |
| Current liabilities | $37.1 million | $42.4 million |
| Long-term debt, net | $48.4 million | $48.1 million |
| Stockholders’ equity | $(13.6) million | $0.1 million |
- Six-month operating cash flow was negative $13.2 million versus negative $5.1 million in 2021.
- Six-month investing cash flow was negative $0.6 million, primarily reflecting $0.5 million of equipment purchases.
- Six-month financing cash flow was negative $0.8 million, including $1.2 million of share withholding repurchases for restricted stock vesting.
- The company reported a current ratio of approximately 3.5 and stated that existing cash and cash from operations are expected to fund obligations for the 12 months following the filing.
- The $50.0 million Hayfin senior secured term loan matures June 30, 2025, with no scheduled principal payments before maturity. The interest rate was 9.0% at June 30, 2022, and the debt is secured by substantially all company assets.
- The company was in compliance with its debt covenants, including a $20.0 million minimum liquidity covenant, as of June 30, 2022.
- Series B convertible preferred stock had a carrying amount of $92.5 million. Accumulated but undeclared dividends were $10.4 million and were not recorded as a balance-sheet liability.
Guidance, Outlook, Risks, and Unusual Items
Management did not provide specific revenue or earnings guidance in the filing. Management expects to incur costs related to clinical trials, regulatory approvals, manufacturing capacity, international expansion, and indemnification obligations. The company expects interest expense to rise as LIBOR increases above the term loan’s 1.5% floor.
- In June 2022, MiMedx entered into a Nordic Bioscience clinical-trial agreement requiring up to $13.3 million in milestone payments, including $2.0 million due within 30 days of execution. No payments had been made as of June 30, 2022; expenses were expected to begin in the third quarter.
- The company remains unable to market Section 351 products in the United States unless and until the FDA grants a BLA. Regulatory failure or further restrictions on EPICORD and AMNIOCORD could adversely affect revenue and could place approximately $2.4 million of cord inventory at risk of write-down.
- Accounts receivable allowance for doubtful accounts increased to $3.5 million from $1.2 million at year-end 2021, reflecting customer credit deterioration.
- The company faces ongoing litigation, regulatory matters, and indemnification obligations related to former officers and the prior Audit Committee investigation. No reserves for legal proceedings were recorded as of June 30, 2022.
- A securities class-action dismissal was under appeal in the Eleventh Circuit. Negotiations with former CEO Parker Petit regarding indemnification-related matters remained ongoing.
- COVID-19 effects had largely been ameliorated and did not materially affect Q2 operations, although the company continued to monitor variants, hospital access, and donor-material availability.
- Management reported effective disclosure controls and no material change in internal control over financial reporting during the quarter.
Investor Verification Checklist
- Verify the company’s ability to replace lost U.S. Section 351 revenue through Advanced Wound Care growth and any future FDA approvals.
- Monitor cash burn, operating cash flow, and liquidity relative to the $20.0 million debt covenant and the $50.0 million 2025 maturity.
- Assess the timing, milestone obligations, and total potential cost of the Nordic Bioscience knee osteoarthritis trial.
- Track accounts receivable aging, bad debt expense, and customer credit deterioration.
- Review the potential dilution and economic claims associated with the Series B preferred stock, including approximately 28.7 million convertible common shares based on accumulated dividends.
- Follow the securities class-action appeal, former-officer indemnification matters, and other litigation for possible cash or earnings impacts.
- Evaluate whether higher research, development, legal, travel, commission, and share-based compensation costs can be supported by future revenue growth.